Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Composition for inhibiting immune cell proliferation comprising sialyllactose or derivative thereof and method thereof

a technology of immune cell proliferation and sialyllactose, which is applied in the direction of dermatological disorders, food ingredients, drug compositions, etc., can solve the problems of affecting the normal regeneration of cartilage tissue that constitutes joints, affecting the normal functioning of cartilage tissue, so as to prevent or treat osteoarthritis, promote cartilage formation, and inhibit the effect of cartilage destruction

Inactive Publication Date: 2020-05-07
CUPIONE CO LTD
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The patent describes a new compound called sialyllactose that can prevent cartilage damage and promote its formation, which can help treat osteoarthritis. It can also reduce allergic reactions and inflammation in atopic dermatitis, which is a skin condition.

Problems solved by technology

In particular, cartilage tissue that constitutes a joint is not normally regenerated in vivo once it is damaged.
If cartilage tissue in a joint is damaged, the cartilage tissue damage impedes daily activities with severe pain.
If the damage becomes chronic, it causes fatal osteoarthritis which interferes with normal life or professional activities.
However, since NSAID-based drugs are primarily intended to temporarily relieve joint inflammation, NSAID-based drugs do not provide adequate treatment for osteoarthritis which is a non-inflammatory arthritis that requires enhancement of cartilage formation and inhibition of cartilage destruction (Pritchard M H et al., Annals of the Rheumatic Diseases, 37:493-503, 1978).
However, it is pointed out that NSAIDs accelerate cartilage damage or have adverse effects on the cardiovascular system, gastrointestinal tract, kidney, liver, etc.
Although this method has been successful in some patients, it cannot be universally applied because the method can be performed only for autologous transplant-eligible patients with less cartilage damage (Peterson L et al., J Bone Joint Surg Am.
However, there have been no reports about prophylactic and therapeutic effects of 3′- or 6′-sialyllactose on osteoarthritis.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Composition for inhibiting immune cell proliferation comprising sialyllactose or derivative thereof and method thereof
  • Composition for inhibiting immune cell proliferation comprising sialyllactose or derivative thereof and method thereof
  • Composition for inhibiting immune cell proliferation comprising sialyllactose or derivative thereof and method thereof

Examples

Experimental program
Comparison scheme
Effect test

example 1

nt of Cytotoxicity of Sialyllactose on Chondrocytes

[0084]Chondrocytes were obtained from cartilage tissues derived from femoral heads, femoral condyles, and tibial plateaus of normal mouse at 5 days after birth. The obtained chondrocytes were cultured in DMEM medium (Gibco, USA) containing 10% (v / v) fetal bovine serum (Gibco, USA), 50 μg / ml of streptomycin (Sigma-Aldrich, USA) and 50 unit / ml of penicillin (Sigma-Aldrich, USA).

[0085]In order to confirm that 3′- or 6′-sialyllactose has no cytotoxicity on chondrocytes, chondrocytes were cultured in a 96-well culture plate at a density of 9×103 cells / well, and then treated with 3′- or 6′-sialyllactose (Genechem Inc., Daejeon, Korea) at a concentration of 0 μM, 10 μM, 50 μM, 100 μM, or 250 μM, followed by incubation in a 5% CO2 incubator at 37° C. for 24 hrs. Cytotoxicity of 3′- or 6′-sialyllactose on chondrocytes was confirmed by measuring absorbance at 450 nm using an EZ-Cytox Cell viability assay kit (DoGen, Korea).

[0086]As a result, ...

example 2

on of Effects of Sialyllactose on Cartilage Formation and Regeneration

2-1: Increase of Expression of Type II Collagen (Col2a1)

[0087]In order to examine effects of 3′- or 6′-sialyllactose on cartilage formation and regeneration, the chondrocytes obtained in Example 1 were incubated for 36 hrs and then treated with 3′- or 6′-sialyllactose at a concentration of 0 μM, 10 μM, 50 μM, 100 μM, or 250 μM, followed by further incubation for 36 hrs.

[0088]Next, in order to perform qRT-PCR, RNA was extracted from the chondrocytes using a TRI reagent (Molecular Research Center Inc.), and cDNA obtained by reverse transcription of RNA was amplified by PCR using primers of SEQ ID NOS: 1 and 2 under condition of annealing temperature of 55° C. to examine expression of type II collagen (Col2a1, 173 bp) which is essential for cartilage formation. As a control group, Gapdh (450 bp, annealing temperature of 58° C.) was examined by using primers of SEQ ID NOS: 3 and 4.

SEQ ID NO: 1: 5′-CACACTGGTAAGTGGGGCAA...

example 3

n of Cartilage Formation and Regeneration Signaling Pathways by Sialyllactose

[0094]Col2a1 expression essential for cartilage formation and regeneration is regulated by a transcription factor Sox-9, and therefore, it was examined whether Sox-9 transcription factor is regulated by 3′-sialyllactose.

[0095]A Sox-9 reporter gene was prepared by inserting 48-bp Sox9 binding site in the first intron of human Col2a1 gene into the upstream of SV40 promoter in pGL3 vector (Zhou G et al., J Biol Chem 1998, 12, 14989-97).

[0096]1 μg of the Sox-9 reporter gene was transfected into chondrocytes using lipofectamine 2000 (Invitrogen) for 3 hrs. The transfected cells were co-treated with 5 ng / ml interleukin 1 beta (IL-1β) and 0 μM, 10 μM, 50 μM, 100 μM, or 250 μM of 3′- or 6′-sialyllactose for 24 hrs, and then chondrocytes were recovered to examine Sox-9 activity by luciferase activity.

[0097]As a result, it was confirmed that Sox-9 activity decreased by IL-1β was restored by 3′- or 6′-sialyllactose (F...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Provided are a composition for inhibiting immune cell proliferation, including sialyllactose or a derivative thereof as an active ingredient, and a method of inhibiting immune cell proliferation, wherein the composition and the method may decrease expression of chemokines, decrease expression of pro-inflammatory cytokines, decrease production of inflammatory mediators, decrease expression of COX2, and decrease production of PEG2, and therefore, may be useful for the prevention or treatment of atopic dermatitis or arthritis.

Description

CROSS REFERENCE TO RELATED APPLICATIONS[0001]The present application is a divisional application of U.S. Ser. No. 16 / 130,522, filed on Sep. 13, 2018, which is a continuation-in-part of international patent application PCT / KR2017 / 010489, filed on Sep. 22, 2017, the text of which is incorporated by reference, and claims the benefit of the filing date of Korean application nos. 10-2017-0067915 filed on May 31, 2017, and 10-2017-0010540 filed on Jan. 23, 2017, the texts of which are also incorporated by reference.TECHNICAL FIELD[0002]The present disclosure relates to a composition for inhibiting immune cell proliferation including sialyllactose or a derivative thereof as an active ingredient, and a method of inhibiting immune cell proliferation.BACKGROUND ART[0003]Osteoarthritis (OA) is a degenerative joint disease primarily caused by inhibition of cartilage extracellular matrix (ECM) synthesis and promotion of cartilage tissue destruction. Many etiological risk factors and pathophysiol...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/702A23L33/125A61P17/00A61P19/02
CPCA61P17/00A61K31/702A23L33/125A61P19/02A23V2002/00A61P29/00A23V2200/318A23V2250/612
Inventor YANG, SIYOUNGJEON, JIMINKANG, LI-JUNGCHO, CHANMI
Owner CUPIONE CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com